vs
Side-by-side financial comparison of James River Group Holdings, Inc. (JRVR) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
James River Group Holdings, Inc. is the larger business by last-quarter revenue ($167.7M vs $164.7M, roughly 1.0× PTC THERAPEUTICS, INC.). James River Group Holdings, Inc. runs the higher net margin — 19.1% vs -82.0%, a 101.1% gap on every dollar of revenue. On growth, James River Group Holdings, Inc. posted the faster year-over-year revenue change (32.4% vs -22.7%). James River Group Holdings, Inc. produced more free cash flow last quarter ($-23.6M vs $-36.6M). Over the past eight quarters, James River Group Holdings, Inc.'s revenue compounded faster (-8.7% CAGR vs -11.5%).
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
JRVR vs PTCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $167.7M | $164.7M |
| Net Profit | $32.1M | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | 14.6% | -43.3% |
| Net Margin | 19.1% | -82.0% |
| Revenue YoY | 32.4% | -22.7% |
| Net Profit YoY | 149.5% | -104.8% |
| EPS (diluted) | $0.59 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $167.7M | $164.7M | ||
| Q3 25 | $172.7M | $211.0M | ||
| Q2 25 | $174.8M | $178.9M | ||
| Q1 25 | $172.3M | $1.2B | ||
| Q4 24 | $126.7M | $213.2M | ||
| Q3 24 | $191.5M | $196.8M | ||
| Q2 24 | $188.3M | $186.7M | ||
| Q1 24 | $201.1M | $210.1M |
| Q4 25 | $32.1M | $-135.0M | ||
| Q3 25 | $1.0M | $15.9M | ||
| Q2 25 | $4.8M | $-64.8M | ||
| Q1 25 | $9.6M | $866.6M | ||
| Q4 24 | $-64.8M | $-65.9M | ||
| Q3 24 | $-39.4M | $-106.7M | ||
| Q2 24 | $7.6M | $-99.2M | ||
| Q1 24 | $15.4M | $-91.6M |
| Q4 25 | 14.6% | -43.3% | ||
| Q3 25 | 1.5% | 1.4% | ||
| Q2 25 | 4.2% | -19.5% | ||
| Q1 25 | 9.3% | 82.5% | ||
| Q4 24 | -57.0% | -76.2% | ||
| Q3 24 | -27.1% | -27.7% | ||
| Q2 24 | 10.7% | -21.5% | ||
| Q1 24 | 16.4% | -21.6% |
| Q4 25 | 19.1% | -82.0% | ||
| Q3 25 | 0.6% | 7.5% | ||
| Q2 25 | 2.7% | -36.3% | ||
| Q1 25 | 5.6% | 73.7% | ||
| Q4 24 | -51.1% | -30.9% | ||
| Q3 24 | -20.6% | -54.2% | ||
| Q2 24 | 4.0% | -53.1% | ||
| Q1 24 | 7.7% | -43.6% |
| Q4 25 | $0.59 | $-1.63 | ||
| Q3 25 | $-0.02 | $0.20 | ||
| Q2 25 | $0.06 | $-0.83 | ||
| Q1 25 | $0.16 | $10.04 | ||
| Q4 24 | $-2.44 | $-0.85 | ||
| Q3 24 | $-1.10 | $-1.39 | ||
| Q2 24 | $0.13 | $-1.29 | ||
| Q1 24 | $0.35 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $260.9M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $538.2M | $-205.3M |
| Total Assets | $4.9B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $260.9M | $1.9B | ||
| Q3 25 | $238.8M | $1.7B | ||
| Q2 25 | $220.0M | $2.0B | ||
| Q1 25 | $279.4M | $2.0B | ||
| Q4 24 | $362.3M | $1.1B | ||
| Q3 24 | $359.8M | $1.0B | ||
| Q2 24 | $672.5M | $1.1B | ||
| Q1 24 | $305.5M | $884.8M |
| Q4 25 | $538.2M | $-205.3M | ||
| Q3 25 | $503.6M | $-155.8M | ||
| Q2 25 | $492.6M | $-206.5M | ||
| Q1 25 | $484.5M | $-185.8M | ||
| Q4 24 | $460.9M | $-1.1B | ||
| Q3 24 | $530.3M | $-1.1B | ||
| Q2 24 | $541.8M | $-980.2M | ||
| Q1 24 | $539.5M | $-893.9M |
| Q4 25 | $4.9B | $2.9B | ||
| Q3 25 | $5.0B | $2.6B | ||
| Q2 25 | $5.0B | $2.6B | ||
| Q1 25 | $4.9B | $2.7B | ||
| Q4 24 | $5.0B | $1.7B | ||
| Q3 24 | $5.0B | $1.8B | ||
| Q2 24 | $4.7B | $1.9B | ||
| Q1 24 | $5.3B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.8M | $-34.3M |
| Free Cash FlowOCF − Capex | $-23.6M | $-36.6M |
| FCF MarginFCF / Revenue | -14.1% | -22.3% |
| Capex IntensityCapex / Revenue | 2.9% | 1.4% |
| Cash ConversionOCF / Net Profit | -0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-17.9M | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.8M | $-34.3M | ||
| Q3 25 | $34.3M | $-66.3M | ||
| Q2 25 | $25.2M | $-58.3M | ||
| Q1 25 | $-51.5M | $870.1M | ||
| Q4 24 | $-247.1M | $-30.0M | ||
| Q3 24 | $-269.9M | $-77.0M | ||
| Q2 24 | $-8.7M | $-71.5M | ||
| Q1 24 | $24.1M | $70.8M |
| Q4 25 | $-23.6M | $-36.6M | ||
| Q3 25 | $33.7M | $-69.7M | ||
| Q2 25 | $24.7M | $-59.6M | ||
| Q1 25 | $-52.7M | $868.4M | ||
| Q4 24 | $-252.0M | $-33.8M | ||
| Q3 24 | $-270.8M | $-77.5M | ||
| Q2 24 | $-9.3M | $-78.8M | ||
| Q1 24 | $23.3M | $61.2M |
| Q4 25 | -14.1% | -22.3% | ||
| Q3 25 | 19.5% | -33.1% | ||
| Q2 25 | 14.1% | -33.3% | ||
| Q1 25 | -30.6% | 73.8% | ||
| Q4 24 | -198.9% | -15.8% | ||
| Q3 24 | -141.4% | -39.4% | ||
| Q2 24 | -4.9% | -42.2% | ||
| Q1 24 | 11.6% | 29.1% |
| Q4 25 | 2.9% | 1.4% | ||
| Q3 25 | 0.4% | 1.6% | ||
| Q2 25 | 0.3% | 0.7% | ||
| Q1 25 | 0.7% | 0.1% | ||
| Q4 24 | 3.9% | 1.8% | ||
| Q3 24 | 0.4% | 0.3% | ||
| Q2 24 | 0.3% | 4.0% | ||
| Q1 24 | 0.4% | 4.6% |
| Q4 25 | -0.59× | — | ||
| Q3 25 | 33.61× | -4.17× | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | -5.38× | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.14× | — | ||
| Q1 24 | 1.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JRVR
| Excess And Surplus Lines | $156.7M | 93% |
| Specialty Admitted Insurance | $10.9M | 7% |
PTCT
Segment breakdown not available.
